We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
As filed with the Securities and Exchange Commission on March 7, 2024Registration No. 333-__________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
00017855302023FYFALSE00017855302023-01-012023-12-3100017855302023-06-30iso4217:USD00017855302024-03-01xbrli:shares00017855302023-10-012023-12-3100017855302023-12-3100017855302022-12-31iso4217:USDxb...
0001785530FALSE00017855302024-03-072024-03-07UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549______________________FORM 8-K______________________CURRENT REPORTPursuant to...
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 – – WTX-124 recommended dose for expansion...
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...
false 0001785530 0001785530 2024-02-09 2024-02-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT...
Table of Contents Filed Pursuant to Rule 424(b)(5)Registration No. 333-264844 PROSPECTUS SUPPLEMENT (To Prospectus dated May 20, 2022) Up to $25,000,000 Common Stock...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.18 | 2.91734197731 | 6.17 | 6.73 | 5.77 | 143683 | 6.0740092 | CS |
4 | -0.06 | -0.936037441498 | 6.41 | 7.305 | 5.77 | 175270 | 6.36072585 | CS |
12 | 1.96 | 44.6469248292 | 4.39 | 8.1939 | 3.86 | 258673 | 5.66182571 | CS |
26 | 4.12 | 184.753363229 | 2.23 | 8.1939 | 1.5735 | 593568 | 3.56748992 | CS |
52 | 3.99 | 169.06779661 | 2.36 | 8.1939 | 1.5735 | 317704 | 3.52479915 | CS |
156 | -11.86 | -65.1290499725 | 18.21 | 23.99 | 1.39 | 220251 | 5.28466588 | CS |
260 | -11.86 | -65.1290499725 | 18.21 | 23.99 | 1.39 | 220251 | 5.28466588 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions